First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy [10]

Gut

Volumn 55, Issue 4, 2006, Pages 585-586

  Salazar, M ^a   Barata, A ^a   Andre S ^a   Venancio J ^a   Francisco, I ^a   Cravo, M ^a   Nobre Leitao C ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADJUVANT THERAPY; ADULT; ANAMNESIS; CANCER RECURRENCE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEOANAL ANASTOMOSIS; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECTUM TUMOR; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; RECTAL NEOPLASMS; RECTUM; TREATMENT OUTCOME;

EID: 33645115523     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.086744     Document Type: Letter

References (6)

1. Pidhorecky I, Cheney R, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behaviour, and management. Ann Surg Oncol 2000;7:705-12.
2. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
3. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
4. Demetri GD, Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
5. Blay JY, Bonvalot S, Casali P, et al. GIST consensus meeting panellists: Consensus meeting for the management of gastrointestinal stromal tumours. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
6. Verweij J, Casali P, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.